Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 févr. 2024 16h01 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of January 29, 2024, the...
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
17 janv. 2024 16h01 HE
|
Vor Biopharma
First patient dosed in company’s second clinical program with initial data expected in second half of 2024Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass.,...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 déc. 2023 16h01 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of December 20, 2023, the...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 déc. 2023 16h01 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of November 29, 2023 the...
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
27 nov. 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
09 nov. 2023 16h01 HE
|
Vor Biopharma
Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor...
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
07 nov. 2023 16h05 HE
|
Vor Biopharma
Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 nov. 2023 16h01 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of October 30, 2023, the...
Vor Bio to Participate in Upcoming Investor Conferences
03 nov. 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
02 nov. 2023 09h01 HE
|
Vor Biopharma
Three oral and two poster presentations accepted by ASHCompany to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and...